Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma by Andrew J. Yee, Jacob P. Laubach, Erica L. Campagnaro, Brea C. Lipe, Omar Nadeem, Robb S. Friedman, Craig E. Cole, Elizabeth K. O’Donnell, Giada Bianchi, Andrew R. Branagan, Robert L. Schlossman, Samantha J. Shapiro, Cynthia C. Harrington, Jill N. Burke, Marilyn T. Gammon, Kathleen J. Lively, Cassandra A. Reimonn, Danielle X. Andrade, Robert Redd, Jens G. Lohr, Kenneth C. Anderson, Paul G. Richardson, Noopur S. Raje

Get full text